Literature DB >> 26890982

Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection.

Yanyan Huai1,2, Shuai Dong1, Ye Zhu2, Xin Li2, Binrui Cao2, Xiang Gao1, Mingying Yang3, Li Wang1, Chuanbin Mao2,4.   

Abstract

Candida albicans (CA) is a kind of fungus that can cause high morbidity and mortality in immunocompromised patients. However, preventing CA infection in these patients is still a daunting challenge. Herein, inspired from the fact that immunization with secreted aspartyl proteinases 2 (Sap2) can prevent the infection, it is proposed to use filamentous phage, a human-safe virus nanofiber specifically infecting bacteria (≈900 nm long and 7 nm wide), to display an epitope peptide of Sap2 (EPS, with a sequence of Val-Lys-Tyr-Thr-Ser) on its side wall and thus serve as a vaccine for preventing CA infection. The engineered virus nanofibers and recombinant Sap2 (rSap2) are then separately used to immunize mice. The humoral and cellular immune responses in the immunized mice are evaluated. Surprisingly, the virus nanofibers significantly induce mice to produce strong immune response as rSap2 and generate antibodies that can bind Sap2 and CA to inhibit the CA infection. Consequently, immunization with the virus nanofibers in mice dramatically increases the survival rate of CA-infected mice. All these results, along with the fact that the virus nanofibers can be mass-produced by infecting bacteria cost-effectively, suggest that virus nanofibers displaying EPS can be a vaccine candidate against fungal infection.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  fungal infection; nanofibers; vaccine; viruses

Mesh:

Substances:

Year:  2016        PMID: 26890982      PMCID: PMC4828319          DOI: 10.1002/adhm.201500930

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  64 in total

Review 1.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

2.  Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase.

Authors:  A R Colina; F Aumont; N Deslauriers; P Belhumeur; L de Repentigny
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Recognition of HIV-derived B and T cell epitopes displayed on filamentous phages.

Authors:  P De Berardinis; L D'Apice; A Prisco; M N Ombra; P Barba; G Del Pozzo; S Petukhov; P Malik; R N Perham; J Guardiola
Journal:  Vaccine       Date:  1999-03-17       Impact factor: 3.641

4.  Murine model of concurrent oral and vaginal Candida albicans colonization to study epithelial host-pathogen interactions.

Authors:  Durdana Rahman; Mukesh Mistry; Selvam Thavaraj; Stephen J Challacombe; Julian R Naglik
Journal:  Microbes Infect       Date:  2007-01-27       Impact factor: 2.700

5.  Epitope mapping Candida albicans proteinase (SAP 2).

Authors:  A Ghadjari; R C Matthews; J P Burnie
Journal:  FEMS Immunol Med Microbiol       Date:  1997-10

6.  Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.

Authors:  Flavia De Bernardis; Haiqun Liu; Rachel O'Mahony; Roberto La Valle; Silvia Bartollino; Silvia Sandini; Steven Grant; Neil Brewis; Ian Tomlinson; Rachel C Basset; John Holton; Ivan M Roitt; Antonio Cassone
Journal:  J Infect Dis       Date:  2006-11-20       Impact factor: 5.226

Review 7.  Advances in combating fungal diseases: vaccines on the threshold.

Authors:  Jim E Cutler; George S Deepe; Bruce S Klein
Journal:  Nat Rev Microbiol       Date:  2006-12-11       Impact factor: 60.633

8.  Self-assembly and mineralization of genetically modifiable biological nanofibers driven by β-structure formation.

Authors:  Hong Xu; Binrui Cao; Anne George; Chuanbin Mao
Journal:  Biomacromolecules       Date:  2011-05-10       Impact factor: 6.988

Review 9.  Immunity to fungal infections.

Authors:  Luigina Romani
Journal:  Nat Rev Immunol       Date:  2004-01       Impact factor: 53.106

10.  Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease.

Authors:  Leah E Cowen; Sheena D Singh; Julia R Köhler; Cathy Collins; Aimee K Zaas; Wiley A Schell; Hamza Aziz; Eleftherios Mylonakis; John R Perfect; Luke Whitesell; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

View more
  9 in total

Review 1.  Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine.

Authors:  Kegan S Sunderland; Mingying Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2017-01-24       Impact factor: 15.336

Review 2.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

3.  Identification of Novel Short BaTiO3-Binding/Nucleating Peptides for Phage-Templated in Situ Synthesis of BaTiO3 Polycrystalline Nanowires at Room Temperature.

Authors:  Yan Li; Binrui Cao; Mingying Yang; Ye Zhu; Junghae Suh; Chuanbin Mao
Journal:  ACS Appl Mater Interfaces       Date:  2016-11-01       Impact factor: 9.229

Review 4.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

Review 5.  Enhancement of Photodynamic Cancer Therapy by Physical and Chemical Factors.

Authors:  Mingying Yang; Tao Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2019-07-10       Impact factor: 15.336

Review 6.  Phages in vaccine design and immunity; mechanisms and mysteries.

Authors:  Christiaan R de Vries; Qingquan Chen; Sally Demirdjian; Gernot Kaber; Arya Khosravi; Dan Liu; Jonas D Van Belleghem; Paul L Bollyky
Journal:  Curr Opin Biotechnol       Date:  2020-12-11       Impact factor: 9.740

7.  Novel nanoscale bacteriophage-based single-domain antibodies for the therapy of systemic infection caused by Candida albicans.

Authors:  Shuai Dong; Hongxi Shi; Donghui Cao; Yicun Wang; Xintong Zhang; Yan Li; Xiang Gao; Li Wang
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

Review 8.  Design, challenge, and promise of stimuli-responsive nanoantibiotics.

Authors:  Julius A Edson; Young Jik Kwon
Journal:  Nano Converg       Date:  2016-10-15

Review 9.  Phage display as a tool for vaccine and immunotherapy development.

Authors:  Krystina L Hess; Christopher M Jewell
Journal:  Bioeng Transl Med       Date:  2019-09-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.